Addressing RVI in the Immunocompromised Patient

Goals for Managing RVI

Prevention

Vaccines, monoclonal antibodies, immunoglobulin products, and public health measures aim to reduce RVIs.¹
Symptom Relief

Decongestants, analgesics, antitussives, and expectorants can be used for mild disease.¹
Therapy

Antiviral therapies are available but are limited by the number of options, a narrow therapeutic window, and susceptibility to mutation.¹

Prophylactic and therapeutic strategies for RVI management

Vaccination

Live, attenuated, or protein-based strategies designed to elicit protective immunity to targeted viruses.¹

View Benefits
Vaccination¹
- Boost or restore immune reponse
View Strategy
IVIG therapy

Used as Ig replacement for broad-spectrum antibody protection.²

View Benefits
IVIG therapy²
- Boost or restore immune reponse
- Bind viral particles
- Anti-inflammatory properties
View Strategy
Hyperimmune IVIG therapy

Used to provide increased titers of polyclonal antibodies against specific pathogens (ie Respigam^®).^2-4

View Benefits
Hyperimmune IVIG therapy³
- Boost or restore immune reponse
- Bind viral particles
- Anti-inflammatory properties
- Standardized titers of RVI antibodies
View Strategy
Monoclonal antibodies

Therapeutic antibodies that target specific epitopes of individual viral surface proteins.¹

View Benefits
Monoclonal antibodies¹
- Bind viral particles
View Strategy
Antiviral therapy

Compounds that inhibit key components of the viral life cycle for acute treatment; not necessarily specific to a virus.¹

View Benefits
Antiviral
therapy¹
- Interfere with viral metabolism
View Strategy

Despite a range of approaches to RVI management of immunocompromised patients, there are still a number of unmet needs.

No known FDA-approved treatment options

for parainfluenza, metapneumovirus, or coronavirus.⁵
<50% effectiveness of vaccines

in immunocompromised patients.⁶
RSV prevention and treatment options are limited to a

select number of patients^7,8

Connect with ADMA to learn more about RVI in immunocompromised patients.

LEARN MORE

IVIG, intravenous immunoglobulin; RSV, respiratory syncytial virus; RVI, respiratory viral infection.

References

1. Papadopoulos NG, et al. J Allergy Clin Immunol. 2017;140(4):921‐932. 2. Durandy A, et al. Clin Exp Immunol. 2009;158(4 suppl):2-13. 3. Boros P, et al. Liver Transpl. 2005;11(12):1469-1480 4. Wu, H., et al. Curr Top Microbiol Immunol 2008;317:103-123 5. Peghin M, Danziger-Isakov L. Prevention and treatment of respiratory virus infection. In: Manuel O, Ison M (eds). Infectious Diseases in Solid-Organ Transplant Recipients. Springer, Cham. 6. Centers for Disease Control and Prevention. Immunogenicity, efficacy, and effectiveness of influenza vaccines. Accessed February 2, 2021. 7. Synagis [prescribing information]. Gaithersburg, MD: MedImmune; 2017. 8. Virazole [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; 2019. 9. Shah JN, Chemaly RF. Blood. 2011;117(10):2755-2763.

Addressing RVI

Goals for Managing RVI

Prophylactic and therapeutic strategies for RVI management

Despite a range of approaches to RVI management of immunocompromised patients, there are still a number of unmet needs.

The ideal therapeutic would clear pathogens and mitigate inflammatory responses.

References